Show simple item record

dc.creatorRizzo, Manfredi
dc.creatorAbate, Nicola
dc.creatorChandalia, Manisha
dc.creatorRizvi, Ali A.
dc.creatorGiglio, Rosaria V.
dc.creatorNikolić, Dragana
dc.creatorGammazza, Antonella Marino
dc.creatorBarbagallo, Ignazio
dc.creatorIsenović, Esma R.
dc.creatorBanach, Maciej
dc.creatorMontalto, Giuseppe
dc.creatorVolti, Giovanni Li
dc.date.accessioned2018-03-01T16:04:45Z
dc.date.available2018-03-01T16:04:45Z
dc.date.issued2015
dc.identifier.issn0021-972X (print)
dc.identifier.issn1945-7197 (electronic)
dc.identifier.urihttp://vinar.vin.bg.ac.rs/handle/123456789/508
dc.description.abstractContext: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; meanage: 57 +/- 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded. Main Outcome Measure(s): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 were assessed. Results: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 +/- 0.4 vs 7.5 +/- 0.4%, P LT .0001). In addition, plasma ghrelin and glutathione concentrations increased (8.2 +/- 4.1 vs 13.6 +/- 7.3 pg/ml, P = .0007 and 0.36 +/- 0.06 vs 0.44 +/- 0.07 nmol/ml, P = .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 +/- 0.05 vs 0.04 +/- 0.07 pg/ml, P = .0487 and 7.7 +/- 7.7 vs 3.6 +/- 1.8 pg/ml, P = .0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. Conclusions: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings seemed to be independent of the known effects of liraglutide on glucose metabolism.en
dc.relationNIH Clinical and Translational Science Award [UL1TR000071]
dc.rightsopenAccessen
dc.sourceJournal of Clinical Endocrinology and Metabolismen
dc.titleLiraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Studyen
dc.typearticleen
dcterms.abstractБанацх, Мациеј; Барбагалло, Игназио; Николић Драгана; Цхандалиа, Манисха; Aбате, Ницола; Исеновић Есма; Монталто, Гиусеппе; Волти, Гиованни Ли; Гиглио, Росариа В.; Риззо, Манфреди; Ризви, Aли A.; Гаммазза, Aнтонелла Марино;
dc.citation.volume100
dc.citation.issue2
dc.citation.spage603
dc.citation.epage606
dc.identifier.wos000353350900065
dc.identifier.doi10.1210/jc.2014-2291
dc.citation.rankM21
dc.identifier.pmid25393640
dc.identifier.scopus2-s2.0-84922569481
dc.identifier.fulltexthttp://vinar.vin.bg.ac.rs//bitstream/id/13149/504.pdf


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record